CYDY CytoDyn Inc.
Debt Financing ·
CytoDyn and the holders of two $28.5 million convertible notes agreed to extend both maturities by 36 months, to April 2029. In return, the company will pay $1,000,000 a month in common stock, and the interest rate falls to 5%.
CytoDyn can sell up to $30 million of common stock to Yorkville Advisors Global over 36 months, at its own discretion and with no warrants attached. The release names no placement agent or counsel, and the annual report says the company will pursue non-dilutive financing in addition to traditional fundraising.
CytoDyn filed a Form S-3 shelf that would let it offer up to $100,000,000 of stock, warrants, subscription rights and units. The stock is quoted on the OTCQB, where it closed at $0.29 on July 24, 2025, and the shelf cannot be used until it takes effect.
CytoDyn Inc. is a clinical-stage biotechnology company focused on the clinical development of leronlimab (also referred to as PRO 140), a humanized monoclonal antibody targeting the C-C chemokine receptor type 5 (CCR5). The company's business centers on leronlimab's potential in solid-tumor oncology. Its strategy includes completing the Phase 2 CLOVER study in relapsed/refractory microsatellite stable colorectal cancer and conducting additional studies in other solid-tumor indications, including metastatic triple-negative breast cancer. CLOVER evaluates leronlimab in combination with trifluridine and tipiracil (TAS-102) plus bevacizumab. The company announced successful completion of enrollment in the CLOVER study on April 21, 2026, and on April 27, 2026 completed enrollment and first dosing of the first participant in its Expanded Access Program for triple-negative breast cancer. On June 4, 2026, Natera, Inc. and CytoDyn announced a strategic collaboration under which Natera will assess CLOVER trial samples and provide real-world data analyses. The company says it will need significant additional funding and will pursue non-dilutive financing, including license agreements, co-development and strategic partnerships. The asset was acquired from Progenics, which led its preclinical and early clinical development through 2011.
| Product or program | What it is | Stage |
|---|---|---|
| leronlimab (PRO 140) | Humanized monoclonal antibody targeting CCR5, studied in solid-tumor oncology | Phase 2 (CLOVER); enrollment completed April 21, 2026 |
| Line | FY ended May 31, 2026 | FY ended May 31, 2025 |
|---|---|---|
| Net income (loss) | -$42.7 million | $3.7 million |
| Cash from operations | -$17.3 million | -$8.8 million |
| Cash and equivalents | $11.9 million | $11.9 million |
Our latest story on this, dated Mar 24, 2026: "CytoDyn extends two $28.5 million convertible notes by 36 months, cuts interest to 5%". The story links the filing or release it is based on. Read the story.
CytoDyn Inc. trades under the ticker CYDY on OTC.
CytoDyn Inc. is listed on OTC.
The SEC Central Index Key (CIK) for CytoDyn Inc. is 1175680. Its filings are on SEC EDGAR.
1,469,518,000 shares as of 2026-09-30, per the cover page of its 10-Q filed 2026-10-14.
Our directory records CytoDyn Inc. under United States.
Our directory classifies CytoDyn Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.
The ISIN recorded for CytoDyn Inc. is US23283M1018.
aibio.space lists CytoDyn Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as DE.
CytoDyn Inc. is a clinical-stage biotechnology company focused on the clinical development of leronlimab (also referred to as PRO 140), a humanized monoclonal antibody targeting the C-C chemokine receptor type 5 (CCR5). The company's business centers on leronlimab's potential in solid-tumor oncology.
leronlimab (PRO 140): Humanized monoclonal antibody targeting CCR5, studied in solid-tumor oncology Stage: Phase 2 (CLOVER); enrollment completed April 21, 2026.
CytoDyn Inc. reported a net loss of $42.7 million for the fiscal year ended May 31, 2026, and used $17.3 million of cash in operations, per its annual report to the SEC.
$16.4 million in cash at Aug 31, 2026, per its 10-Q.
Our latest story on CytoDyn, dated Mar 24, 2026: "CytoDyn extends two $28.5 million convertible notes by 36 months, cuts interest to 5%". CytoDyn and the holders of two $28.5 million convertible notes agreed to extend both maturities by 36 months, to April 2029. In return, the company will pay $1,000,000 a month in common stock, and the interest rate falls to 5%. Source.
Disclosed a shareholder lawsuit, subpoena or other legal matter. SEC Form 10-K. Source
Filed a registration statement for a share offering. SEC Form S-1. Source
Reported a financing. SEC Form 8-K (Items 1.01). Source
Disclosed a shareholder lawsuit, subpoena or other legal matter. SEC Form 10-Q. Source
Disclosed a shareholder lawsuit, subpoena or other legal matter. SEC Form 8-K (Items 8.01). Source
Reported an unregistered sale of its securities. SEC Form 8-K (Items 1.01,3.02,7.01,9.01). Source
Disclosed a shareholder lawsuit, subpoena or other legal matter. SEC Form 10-K. Source
Set up an at-the-market program to sell shares over time. SEC Form S-3. Source
Reported a change of independent auditor. SEC Form 8-K (Items 4.01,9.01). Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio